嘉必优（688089.SH） 1H25 公司业绩同比持续增长，ARA&DHA 基石产品需求持续增长 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 444 | 556 | 703 | 834 | 964 | | 增长率 yoy（%） | 2.4 | 25.2 | 26.5 | 18.7 | 15.5 | | 归母净利润（百万元） | 91 | 124 | 190 | 220 | 289 | | 增长率 yoy（%） | 41.9 | 35.9 | 52.6 | 16.0 | 31.6 | | ROE（%） | 5.8 | 7.7 | 10.7 | 11.2 | 13.1 | | EPS 最新摊薄（元） | 0.54 | 0.74 | 1.13 | 1.31 | 1.72 | | P/E（倍） | 53.1 | 39.1 | 25.6 | 22.1 | 16.8 | | P/B（倍） | 3.3 | 3.1 | 2.8 | 2.6 | 2.3 | 资料来源：公 ...

Core Viewpoint - The company Jia Bi You announced the termination of its acquisition of 63.21% equity in Ou Yi Biological after nearly 10 months of planning, citing changes in the external market environment as the reason for this cautious decision [2][6]. Summary by Sections Termination Reasons - Jia Bi You's latest announcement indicated that the termination of the acquisition was due to the failure to reach an agreement on core transaction terms, and the company has withdrawn its application documents [4][6]. Background of the Acquisition - Since October 29 of the previous year, Jia Bi You had been planning a major asset restructuring, initially aiming to acquire 65% of Ou Yi Biological's equity. This was later adjusted to 63.21% and involved a reduction in the number of transaction parties from 14 to 13 [7][8]. - The adjusted proposal included issuing 29.77 million shares at a price of 19.29 yuan per share, totaling a transaction price of 830.6 million yuan, which would have resulted in a significant goodwill addition of 721 million yuan, accounting for 43.3% of total assets and 47.21% of net assets as of September 30, 2024 [7][8]. Financial Performance - In the first half of the year, Jia Bi You reported a revenue of 307 million yuan, representing a year-on-year increase of 17.6%, and a net profit attributable to shareholders of 108 million yuan, reflecting a growth of 59.01% [8].

Core Viewpoint - The company Jabiou has decided to terminate its plan to acquire 63.21% of Ouyi Biological after approximately 10 months of planning, citing changes in the external market environment as the reason for this cautious decision [1][3]. Group 1: Acquisition Details - The acquisition was initially announced on October 29, leading to a stock price increase of nearly 40% by August 30, with the latest stock price at 28.82 yuan per share and a total market capitalization of 4.9 billion yuan [1]. - The company had adjusted its acquisition plan from 65% to 63.21% and reduced the number of investors involved from 14 to 13, with a total transaction price of 830.6 million yuan, which included 574.3 million yuan in stock and 256.3 million yuan in cash [5][6]. - The acquisition was expected to add 721 million yuan in goodwill, representing 43.3% of the company's total assets and 47.21% of its net assets as of September 30, 2024 [6]. Group 2: Financial Performance - In the first half of the year, the company reported a revenue of 307 million yuan, reflecting a year-on-year growth of 17.6%, while the net profit attributable to shareholders increased by 59.01% to 108 million yuan [7]. Group 3: Business Operations - The company stated that the termination of the acquisition would not adversely affect its daily operations or harm the interests of shareholders, particularly minority shareholders [3]. - Jabiou is recognized as a pioneer in the domestic market for producing polyunsaturated fatty acids and fat-soluble nutrients through microbial synthesis, and it has successfully commercialized products like algal oil DHA and SA [6].

Core Viewpoint - Jia Bi You announced the termination of the acquisition of 63.21% equity in Ou Yi Biological after approximately 10 months of planning, citing changes in the external market environment as the reason for this cautious decision [2][6]. Group 1: Termination Reasons - The company stated that it did not reach an agreement on the core terms of the transaction, leading to the decision to terminate the acquisition and withdraw the application documents [4]. - The termination was made after thorough communication and consultation with relevant parties, and there are no liabilities for breach of contract for the listed company or related parties [6]. Group 2: Transaction Background - Since the announcement of the major asset restructuring on October 29 last year, Jia Bi You's stock resumed trading on November 12 and recorded a 20% increase, with a nearly 40% rise in stock price by August 30, reaching 28.82 yuan per share and a total market value of 4.9 billion yuan [2][6]. - The initial plan was to acquire 65% of Ou Yi Biological's equity, which was later adjusted to 63.21%, with the number of transaction parties reduced from 14 to 13 [9]. - The adjusted plan included issuing 29.77 million shares at a price of 19.29 yuan per share, totaling 5.743 billion yuan in share payment and 2.563 billion yuan in cash, amounting to a total transaction price of 8.306 billion yuan [9][10]. Group 3: Financial Performance - In the first half of the year, Jia Bi You achieved operating revenue of 307 million yuan, a year-on-year increase of 17.6%, and a net profit attributable to shareholders of 108 million yuan, up 59.01% year-on-year [11].

Core Viewpoint - The company Jabiou has decided to terminate its acquisition plan for a stake in Ouyi Biotechnology due to changes in the external market environment and after thorough communication with relevant parties [2][3]. Group 1: Acquisition Plan - Jabiou initially planned to acquire 63.21% of Ouyi Biotechnology's shares for approximately 831 million yuan, while also issuing shares to raise matching funds from no more than 35 specific investors [2]. - The acquisition was notable due to an asset appraisal increase of 441.23%, which would have resulted in a goodwill increase of 721 million yuan for Jabiou [2]. - The acquisition plan underwent several adjustments, including a reduction in the stake from 65% to 63.21% and changes in the performance compensation calculation method [2][3]. Group 2: Business Operations - Despite the termination of the acquisition, Jabiou stated that its business operations remain normal and that the decision will not adversely affect daily operations or harm the interests of shareholders, particularly minority shareholders [3]. - The company continues to focus on its strategic goals and aims to enhance its synthetic biology technology system, including omics technology [3]. - In the first half of the year, Jabiou reported a revenue of 307 million yuan, representing a year-on-year growth of 17.6%, and a net profit attributable to shareholders of 108 million yuan, reflecting a 59.01% increase [3].

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company reported a total revenue of 307 million yuan in H1 2025, representing a year-on-year increase of 17.60%, and a net profit attributable to the parent company of 108 million yuan, up 59.01% [1] - The growth in revenue is primarily driven by the domestic market, with domestic product sales increasing by 28.66% year-on-year, while overseas product sales grew by 2.38% [2] - The company's gross margin improved to 49.68% in H1 2025, an increase of 7.59 percentage points year-on-year, attributed to enhanced production efficiency and cost optimization [3] - The demand for ARA and DHA, key products of the company, is expected to grow due to the implementation of new national standards for infant formula and the expiration of major patents held by competitors [4] Summary by Sections Financial Performance - In H1 2025, the company achieved a gross profit margin of 49.68%, with a net profit margin of 35.19%, reflecting strong operational efficiency [3] - The company’s sales expenses decreased by 24.32% year-on-year, while management expenses increased by 21.84% due to acquisition-related costs [3] Market Opportunities - The new national standards for infant formula, effective from February 22, 2023, are expected to drive demand for ARA and DHA [4] - The expiration of DSM's major patents in June 2023 presents an opportunity for the company to increase its market share in overseas ARA sales [4] - The Omega-3 market, particularly for DHA, is expanding into functional foods and clinical nutrition, indicating strong demand across various consumer segments [4] Profit Forecast - The company is projected to achieve net profits of 175.21 million yuan, 212.09 million yuan, and 251.48 million yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 41.06%, 21.05%, and 18.57% [5]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [6] Core Views - The company reported a revenue of 307 million yuan for the first half of 2025, representing a year-on-year increase of 17.60%, and a net profit of 108 million yuan, up 59.01% year-on-year [1] - The growth in revenue is primarily driven by increased sales of ARA and DHA products to domestic customers, supported by new national standards, fertility subsidies, and a shift in major clients from fish oil DHA to algae oil DHA [2] - The company has improved its profit margins significantly, with a gross margin nearing 50% and a net margin of 35%, both up by 8 and 9 percentage points respectively compared to the previous year [2] - The company is leveraging synthetic biology and AI to enhance its product offerings and expand into new application areas, including the development of high-value molecules and enzymes [3] - The company has a strong product pipeline, particularly in the HMO sector, with 2'-FL receiving approval and a production capacity of 200-300 tons per year [3] Financial Performance - For 2025, the company is projected to achieve total revenues of 702.42 million yuan, with net profits of 176.95 million yuan, reflecting significant growth rates of 26.43% and 42.46% respectively [4] - The company’s EBITDA is expected to reach 255.72 million yuan in 2025, with a steady increase in subsequent years [5] - The earnings per share (EPS) is projected to grow from 0.54 yuan in 2023 to 1.05 yuan in 2025 [5] Market Position - The company operates in the basic chemicals and chemical products industry, with a current market capitalization of approximately 4.78 billion yuan [7] - The company has a total share capital of 168.31 million shares, with a net asset value per share of 9.66 yuan [7]

Investment Rating - The investment rating for the company is "Buy" [1]. Core Views - The company reported strong performance in Q2, with revenue of 307 million yuan, a year-on-year increase of 17.60%, and a net profit attributable to shareholders of 108 million yuan, up 59.01% year-on-year [1][3]. - The domestic business has driven growth, particularly in the context of the new national standard for milk powder, while overseas revenue remained stable [3]. - The company's gross margin in Q2 reached 50.63%, an increase of 7.24 percentage points year-on-year, attributed to improved capacity utilization and cost reduction [3]. - The company is actively pursuing mergers and acquisitions, with ongoing collaborations with existing clients and new partnerships, such as with Abbott [3]. Financial Summary - For the first half of 2025, the company achieved total revenue of 307 million yuan, with a net profit of 108 million yuan [1]. - The projected financials for 2025-2027 include an EPS of 0.99 yuan, 1.14 yuan, and 1.30 yuan, respectively, with corresponding P/E ratios of 30X, 26X, and 23X [3][4]. - The company expects continued growth in ARA and DHA products, with potential new applications for HMO in the domestic market [3].

Core Viewpoint - The company, Jiabiou, reported strong financial performance in the first half of 2025, with significant growth in revenue and net profit, driven by core product sales and market expansion [2][3][4]. Financial Performance - Jiabiou achieved a revenue of 307 million yuan, representing a year-on-year increase of 17.6% [2] - The net profit attributable to shareholders reached 108 million yuan, marking a year-on-year growth of 59.01% [2] - The non-deductible net profit was approximately 99.92 million yuan, with an impressive growth of 88.51% year-on-year [2] - The overall gross margin improved from 42.09% in the same period of 2024 to 49.68% in 2025 [4] Core Product Growth - The growth in revenue was primarily driven by the sales of core products ARA and DHA, with increasing demand due to new national standards for infant formula and rising maternal consumption [3] - Jiabiou has established long-term partnerships with major companies such as Nestlé and Danone, expanding its market presence to over 30 countries [3] Profitability Enhancement - The significant increase in net profit outpaced revenue growth, indicating improved profitability due to enhanced production efficiency and optimized product and customer structures [4] - The company reduced sales expenses by 24.32% year-on-year, contributing to increased profit margins [4] Emerging Business Opportunities - Jiabiou's entry into the cosmetics market with its product, N-acetylgalactosamine, opens new market opportunities, driven by consumer demand for natural and effective cosmetic ingredients [5] - The company is leveraging its synthetic biology platform to develop high-value products, enhancing its competitive edge in the industry [6] Industry Outlook - The market for nutritional supplements and functional foods is expected to grow, benefiting Jiabiou as a leading supplier in the microbial synthesis nutrient sector [6][7] - The company is well-positioned to capitalize on trends in human nutrition, animal nutrition, and cosmetics, with a focus on high-quality products and innovative technologies [7][8]

Core Viewpoint - The company has implemented a "Quality Improvement, Efficiency Enhancement, and Return to Investors" action plan, achieving significant growth in net profit and expanding its product offerings in various sectors, including infant nutrition, animal nutrition, and beauty care [1][2][5]. Group 1: Business Development - The company achieved a net profit of 108 million yuan, a year-on-year increase of 59.01% [1]. - In the infant nutrition sector, the demand for ARA and algal oil DHA products has steadily increased, with significant contributions from core customer sales growth [1]. - The company has successfully advanced collaborations with major international clients such as Danone, Nestlé, and Abbott, focusing on algal oil DHA products and HMOs [1][2]. Group 2: Product Innovation - The company has developed EncapDHA algal oil emulsion, which can be used in various functional food applications [2]. - In the animal nutrition sector, the company launched 27 new fatty acid products, enhancing its B2C business through integrated operations [2]. - The company is actively developing high-value products such as 2'-FL, 3-FL, and EPA, with successful pilot tests and regulatory submissions [4]. Group 3: Research and Development - The company invested 19.76 million yuan in R&D in the first half of 2025, employing 97 R&D personnel and holding 191 authorized patents [2][3]. - The company is advancing its AI and synthetic biology strategy, enhancing its intelligent R&D platform and bioinformatics capabilities [3]. Group 4: Operational Efficiency - The company has implemented a digital transformation strategy, improving supply chain data analysis and decision-making capabilities [5]. - The company achieved record production levels through capacity optimization and digital management [5]. Group 5: Corporate Governance - The company has maintained effective governance practices, holding multiple board meetings and enhancing its ESG governance framework [6][7]. - The company is focused on improving the capabilities of its key personnel through training and development initiatives [7]. Group 6: Investor Relations - The company emphasizes shareholder returns through cash dividend distributions and potential share buybacks, with plans to repurchase shares within a specified range [8][9]. - The company is actively engaging with investors through various communication channels and events to ensure transparency and information dissemination [10].